Results from another 12 breast cancer patients demonstrated a significant reduction in HDL-C and ApoA-I and an elevation in ApoB after the treatment of either doxorubicin and cyclophosphamide followed by paclitaxel or epirubicin, cyclophosphamide and 5-Fu followed by docetaxel [10]. Here, APOA1 is linked to breast cancer.